The reimbursement question matters more than many investors admit. If payors resist one-time curative pricing, the TAM that appears in biotech decks may not translate into cash flows.
♥ 0 Thanks from members
Peer Perspective on Regenerative Medicine & Cell Therapy
Posted 6/28/2026